Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 476

1.

The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.

Solèr M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, Thirlwell J, Gupta N, Della Cioppa G.

Eur Respir J. 2001 Aug;18(2):254-61. Erratum in: Eur Respir J 2001 Oct;18(4):739-40.

2.

Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).

Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, Taylor AF, Rohane P.

Pediatrics. 2001 Aug;108(2):E36.

PMID:
11483846
3.

Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody.

Silkoff PE, Romero FA, Gupta N, Townley RG, Milgrom H.

Pediatrics. 2004 Apr;113(4):e308-12.

PMID:
15060258
4.

Omalizumab is effective in the long-term control of severe allergic asthma.

Lanier BQ, Corren J, Lumry W, Liu J, Fowler-Taylor A, Gupta N.

Ann Allergy Asthma Immunol. 2003 Aug;91(2):154-9.

PMID:
12952109
5.

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.

Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N.

J Allergy Clin Immunol. 2001 Aug;108(2):184-90.

PMID:
11496232
6.

The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma.

Buhl R, Hanf G, Solèr M, Bensch G, Wolfe J, Everhard F, Champain K, Fox H, Thirlwell J.

Eur Respir J. 2002 Nov;20(5):1088-94.

7.

Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma.

Berger W, Gupta N, McAlary M, Fowler-Taylor A.

Ann Allergy Asthma Immunol. 2003 Aug;91(2):182-8.

PMID:
12952113
8.

Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma.

Buhl R, Solèr M, Matz J, Townley R, O'Brien J, Noga O, Champain K, Fox H, Thirlwell J, Della Cioppa G.

Eur Respir J. 2002 Jul;20(1):73-8.

9.

Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.

Holgate ST, Chuchalin AG, Hébert J, Lötvall J, Persson GB, Chung KF, Bousquet J, Kerstjens HA, Fox H, Thirlwell J, Cioppa GD; Omalizumab 011 International Study Group.

Clin Exp Allergy. 2004 Apr;34(4):632-8.

PMID:
15080818
10.
11.

Omalizumab for asthma in adults and children.

Normansell R, Walker S, Milan SJ, Walters EH, Nair P.

Cochrane Database Syst Rev. 2014 Jan 13;(1):CD003559. doi: 10.1002/14651858.CD003559.pub4. Review.

PMID:
24414989
12.

Spotlight on omalizumab in allergic asthma.

Bang LM, Plosker GL.

BioDrugs. 2004;18(6):415-8. Review.

PMID:
15571425
13.

Omalizumab improves asthma-related quality of life in children with allergic asthma.

Lemanske RF Jr, Nayak A, McAlary M, Everhard F, Fowler-Taylor A, Gupta N.

Pediatrics. 2002 Nov;110(5):e55.

PMID:
12415061
14.

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, Fox H, Blogg M, Surrey K.

Allergy. 2005 Mar;60(3):309-16.

15.

Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality.

Holgate S, Bousquet J, Wenzel S, Fox H, Liu J, Castellsague J.

Curr Med Res Opin. 2001;17(4):233-40.

PMID:
11922396
16.

Omalizumab protects against allergen- induced bronchoconstriction in allergic (immunoglobulin E-mediated) asthma.

Zielen S, Lieb A, De La Motte S, Wagner F, de Monchy J, Fuhr R, Munzu C, Koehne-Voss S, Rivière GJ, Kaiser G, Erpenbeck VJ.

Int Arch Allergy Immunol. 2013;160(1):102-10. doi: 10.1159/000339243. Epub 2012 Aug 28.

PMID:
22948442
17.

Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.

Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M, Fox H, Surrey K.

Allergy. 2004 Jul;59(7):709-17.

18.

Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma.

Kulus M, Hébert J, Garcia E, Fowler Taylor A, Fernandez Vidaurre C, Blogg M.

Curr Med Res Opin. 2010 Jun;26(6):1285-93. doi: 10.1185/03007991003771338.

PMID:
20377320
19.

Omalizumab: a review of its use in the management of allergic asthma.

Bang LM, Plosker GL.

Treat Respir Med. 2004;3(3):183-99. Review.

PMID:
15219177
20.

Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma.

Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF.

J Allergy Clin Immunol. 2009 Dec;124(6):1210-6. doi: 10.1016/j.jaci.2009.09.021.

PMID:
19910033

Supplemental Content

Support Center